Association study of an SNP combination pattern in the dopaminergic pathway in paranoid schizophrenia: A novel strategy for complex disorders

Molecular Psychiatry

Volumn 9, Issue 5, 2004, Pages 510-521

  Xu, Q ^a,b   Jia, Y B ^a,b   Zhang, B Y ^a,b   Zou, K ^a,b   Tao, Y B ^a,b   Wang, Y P ^a,b   Qiang, B Q ^a,b   Wu, G Y ^a   Shen, Y ^a,b,f   Ji, H K ^c   Huang, Y ^c   Sun, X Q ^c   Ji, L ^c   Li, Y D ^c   Yuan, Y B ^d   Shu, L ^d   Yu, X ^d   Shen, Y C ^d   Yu, Y Q ^e   Ju, G Z ^e   Liu, Shu Zheng ^e   Shi, Jie Ping ^e   more..

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c TSINGHUA UNIVERSITY   (China)

^d PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^e JILIN UNIVERSITY   (China)

^f INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Clinial subgroup; Complex disorder; Dopamine metabolic pathway; Effective SNP combination pattern; Potential effective dynamic effects; Schizophrenia; Single nucleotide polymophism; Susceptibility genotype combinations

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 3; CATECHOL METHYLTRANSFERASE; DOPAMINE; ISOENZYME; NORADRENALIN; UNCLASSIFIED DRUG;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOPAMINE METABOLISM; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

ADOLESCENT; ADULT; ALDEHYDE DEHYDROGENASE; ASIAN CONTINENTAL ANCESTRY GROUP; CATECHOL O-METHYLTRANSFERASE; CLUSTER ANALYSIS; COHORT STUDIES; COMPUTATIONAL BIOLOGY; DOPAMINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIFACTORIAL INHERITANCE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA, PARANOID;

EID: 3142555952     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001472     Document Type: Article

References (48)

1. Shastry BS. Recent developments in the genetics of schizophrenia. Neurogenetics 1999; 2: 149-154.
2. Jurewicz I, Owen RJ, O'Donovan MC, Owen MJ. Searching for susceptibility genes in schizophrenia. Eur Neuropsychopharmacol 2001; 11: 395-398.
3. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002; 25: 409-432.
4. Carrasquillo MM, McCallion AS, Puffenberger EG, Kashuk CS, Nouri N, Chakravarti A. Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease. Nat Genet 2002; 32: 237-244.
5. Welch BL. On the comparison of several mean values: an alternative approach. Biometrika 1950; 38: 330-336.
6. Holland JH. Adaptation in Natural and Artificial Systems. MIT Press: Cambridge, MA, 1992.
7. Goldberg DE. Genetic Algorithms in Search, Optimization, and Machine Learning. Addison-Wesley Publishing Company, Inc., 1989.
8. Ramsey FL, Schafer DW. The Statistical Sleuth - A Course in Methods of Data Analysis, 2nd edn Thomson Learning, Inc.: Stannford, 2002.
9. Duda RO, Hart PE, Stork DG. Pattern Classification. Wiley & Sons, Inc.: New York, 2001.
10. Wu CFJ. Jackknife, bootstrap, and other resampling methods in regression analysis. Ann Statist 1986; 14: 1261-1295.
11. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall: London, 1993.
12. Carlin BP, Louis TA. Bayes and Empirical Bayes Methods for Data Analysis. Chapman & Hall: London, 1996.
13. Gelfand AE, Smith AFM. Sampling based approaches to calculating marginal densities. J Am Statist Assoc 1990; 398-409.
14. Kiberstis P, Roberts L. It's not just the genes. Science 2002; 296: 685.
15. Phillips TJ, Belknap JK. Complex-trait genetics: emergence of multivariate strategies. Nat Rev Neurosci 2002; 3: 478-485.
16. Belknap JK. QTL analysis and genomewide mutagenesis in mice. Behav Genet 2001; 31: 5-15.
17. Flint J, Mott R. Finding the molecular basis of quantitative traits: successes and pitfalls. Nat Rev Genet 2001; 2: 437-445.
18. Brookes AJ. Rethinking genetic strategies to study complex diseases. Trends Mol Med 2001; 7: 512-516.
19. Andreason NC. Schizophrenia: the fundamental questions. Brain Res Rev 2000; 31: 106-112.
20. Andreason NC. Positive and negative symptoms of schizophrenia: past, present, and future. Acta Psychiatr Scand 1994; 90: 51-59.
21. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical descriptions and Diagnostic Guidelines. World Health Organization: Geneva, 2001.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn American Psychiatric Association: Washington, DC, 1994.
23. World Health Organization. Schedules for Clinical Assessment in Neuropsychiatry (Version 2.1). World Health Organization: Geneva, 1999.
24. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev 2000; 31: 342-349.
25. Chao HM, Richardson MA. Aromatic amino acid hydroxylase genes and schizophrenia. Am J Med Genet 2002; 114: 626-630.
26. Wei J, Ramchand CN, Hemmings GP. Taq1 polymorphic sites at the human dopamine beta-hydroxylase gene. Psychiatr Genet 1998; 8: 19-24.
27. Himei A, Koh J, Sakai J, Inada Y, Akabame K, Yoneda H. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms. Psychiatry Clin Neurosci 2002; 56: 97-102.
28. Lehmann EL. Nonparametric Statistical Methods Based on Ranks. McGraw-Hill: New York, 1975.
29. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945; 1: 80-83.
30. Phillips TJ, Hen R, Crabbe JC. Complications associated with genetic background effects in research using knockout mice. Psychophamacology 1999; 147: 5-7.
31. Nelson M, Kardia SLR, Ferrell RE, Sing CF. A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res 2001; 11: 458-470.
32. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138-147.
33. Moore JH, Hahn LW. A cellular automata approach to detecting interactions among single-nucleotide polymorphisms in complex multifactorial diseases. Pacific Symp Biocomput 2002; 7: 53-64.
34. Kobayashi K. Role of catecholamine signaling in brain and nervous system functions: new insights from mouse molecular genetic study. J Invest Dermatol Symp Proc 2001; 6: 115-121.
35. Bertolucci-D'Angio M, Serrano A, Scatton B. Mesocorticolimbic dopaminergic systems and emotional states. J Neurosci Methods 1990; 34: 135-142.
36. Tzschentke TM. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 2001; 63: 241-320.
37. Glenthoj B, Mogensen J, Laursen H, Holm S, Hemmingsen R. Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia. Brain Res 1993; 619: 39-54.
38. Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 1983; 35: 53-68.
39. Liou YJ, Tsai SJ, Hong CJ, Wang YC, Lai IC. Association analysis of a functional catechol-o-methyltransferase gene polymorphism in schizophrenic patients in Taiwan. Neuropsychobiology 2001; 43: 11-14.
40. Yamamoto K, Ozawa N, Shinba T, Hoshino T, Yoshii M. Possible noradrenergic dysfunction in schizophrenia. Brain Res Bull 1994; 35: 529-543.
41. Friedmau JI, Adler DN, Davis KL. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry 1999; 46: 1243-1252.
42. Klimek V, Rajkowska G, Luker SN, Dilley G, Meltzer HY, Overholser JC et al. Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology 1999; 21: 69-81.
43. Antelman SM, Caggiula AR. Norepinephrine-dopamine interactions and behavior. Science 1977; 195: 646-653.
44. Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993; 262: 578-580.
45. Simpson GM, Shih JC, Chen K, Flowers C, Kumazawa T, Spring B. Schizophrenia, monoamine oxidase activity, and cigarette smoking. Neuropsychopharmacology 1999; 20: 392-394.
46. Lim LC, Powell JF, Murray R, Gill M. Monoamine oxidase A gene and bipolar affective disorder. Am J Hum Genet 1994; 54: 1122-1124.
47. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW et al. Role of genotype in the cycle of violence in maltreated children. Science 2002; 297: 851-854.
48. Bray NJ, Qwen MJ. Searching for schizophrenia genes. Trends Mol Med 2001; 7: 169-174.